Angela Chin
Physician Assistant · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 6
Offices
6 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center · Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Angela Chin’s office to ask if they take your plan before you enroll.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical CenterOakland, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 130.09 (87.72 to 172.46) · 109 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.274, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.227, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Alta Bates Summit Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 130.09 (87.72 to 172.46) · 109 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.274 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.227 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0.06 to 1.94) · 1,209 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.88 (0.6 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.9 · 105 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.8 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 447 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.7 · 341 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.2 · 381 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 2,811 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.31) · 7,167 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,659 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.93 (0.92 to 4.94) · 1,668 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.25 (0 to 2.75) · 580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.67 (1.19 to 4.15) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.17 (0.33 to 12.02) · 633 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.11 (4.67 to 11.55) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 309 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.39 (0 to 0.96) · 6,085 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 217 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.724 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.425 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.716 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.7 · 416 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 606 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.4 · 359 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.8 · 555 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -14.4 · 358 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16 · 382 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.1 (3.2 to 8.2) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.3 to 16) · 25 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.5 · 232 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.9 · 56 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 152 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.8 (11.1 to 20) · 251 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 579 cases | No different | Jan 2024 – Dec 2024 |
What patients said (535 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$68,936
Medicare paid this office $68,936 for 527 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 225 | $27,144 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 128 | $13,883 | $89 |
| Long return visit (40+ min) | 52 | $8,338 | $141 |
| New patient visit (30+ min) | 51 | $4,603 | $90 |
| Hospital discharge day management, more than 30 minutes | 46 | $3,951 | $86 |
See all 9 services
| Return visit (30+ min) | 225 | $27,144 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 128 | $13,883 | $89 |
| Long return visit (40+ min) | 52 | $8,338 | $141 |
| New patient visit (30+ min) | 51 | $4,603 | $90 |
| Hospital discharge day management, more than 30 minutes | 46 | $3,951 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $2,637 | $98 |
| Programming of dual lead pacemaker system | 34 | $948 | $28 |
| Programming of dual lead implantable defibrillator system | 11 | $503 | $42 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 13 | $176 | $13 |
Who their Medicare patients are
527 Original Medicare patients in 2024. Average age 78 · Under 65 5% · 85 and older 25% · Women 47% · Also on Medicaid 32% · Health risk score 2.03. Above the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 75% · Atrial fibrillation 61% · Coronary heart disease 55% · Heart failure 52% · Chronic kidney disease 46% · Diabetes 37% · Depression 22% · COPD 20% · Stroke 20% · Cancer 18% · Dementia 13%.
The office billed $279,568, Medicare allowed $88,534 and paid $68,936; for 748 services of 27 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 527 | 748 | 78 | 2.03 | $279,568 | $68,936 |
| 2023 | 312 | 330 | 79 | 1.84 | $135,703 | $29,507 |
| 2022 | 940 | 1,110 | 79 | 1.61 | $444,071 | $93,419 |
| 2021 | 974 | 1,216 | 79 | 1.51 | $480,927 | $103,044 |
| 2020 | 999 | 1,167 | 80 | 1.62 | $345,318 | $69,218 |
| 2019 | 1,140 | 1,426 | 79 | 1.66 | $604,315 | $106,624 |
| 2018 | 1,062 | 1,403 | 79 | 1.62 | $540,368 | $106,621 |
| 2017 | 513 | 605 | 78 | 1.68 | $217,293 | $47,222 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Return visit (30+ min) | 277 | $25,758 | $89 |
2022: 6 services
| Return visit (30+ min) | 855 | $83,407 | $87 |
| Long return visit (40+ min) | 35 | $4,463 | $121 |
| Short return visit (20+ min) | 35 | $1,820 | $52 |
| Influenza vaccine split virus, preservative free | 18 | $1,234 | $69 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 18 | $906 | $50 |
| Administration of influenza virus vaccine | 18 | $552 | $31 |
2021: 8 services
| Return visit (30+ min) | 875 | $94,591 | $91 |
| Long return visit (40+ min) | 17 | $2,458 | $145 |
| Telephone medical discussion with physician, 11-20 minutes | 53 | $1,456 | $27 |
| Programming of dual lead pacemaker system | 26 | $1,390 | $53 |
| Influenza vaccine split virus, preservative free | 18 | $1,170 | $65 |
| Short return visit (20+ min) | 12 | $748 | $62 |
| Administration of influenza virus vaccine | 18 | $327 | $18 |
| Telephone medical discussion with physician, 21-30 minutes | 14 | $277 | $20 |
2020: 6 services
| Return visit (30+ min) | 553 | $35,650 | $58 |
| Telephone medical discussion with physician, 21-30 minutes | 166 | $14,585 | $83 |
| Telephone medical discussion with physician, 11-20 minutes | 243 | $13,512 | $54 |
| Telephone medical discussion with physician, 5-10 minutes | 50 | $1,671 | $33 |
| Programming of dual lead pacemaker system | 25 | $1,497 | $58 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 24 | $150 | $6 |
2019: 3 services
| Return visit (30+ min) | 1,088 | $100,637 | $76 |
| Programming of dual lead pacemaker system | 63 | $3,066 | $45 |
| Long return visit (40+ min) | 16 | $1,800 | $113 |
2018: 2 services
| Return visit (30+ min) | 1,023 | $101,198 | $79 |
| Programming of dual lead pacemaker system | 79 | $3,517 | $40 |
2017: 2 services
| Return visit (30+ min) | 463 | $43,805 | $82 |
| Programming of dual lead pacemaker system | 45 | $2,084 | $45 |
Medicaid work
$2,370 in 2022
Medicaid paid $2,370 for 124 billed services this clinician did in 2022, up to 35 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 83 | $2,370 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 41 | $0 |
| 2022 | 124 | 2 | 35 | $2,370 |
| 2021 | 58 | 2 | 30 | $950 |
| 2020 | 225 | 4 | 75 | $995 |
| 2019 | 137 | 2 | 79 | $581 |
| 2018 | 245 | 2 | 27 | $2,504 |
See the largest Medicaid services in earlier years
2021
| Return visit (30+ min) | 43 | $950 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 15 | $0 |
2020
| Return visit (30+ min) | 120 | $883 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 11-20 minutes of medical discussion | 56 | $112 |
| Advance Care Planning discussed and documented advance care plan or surrogate decision maker documented in the medical record (DEM) (GER, Pall Cr) | 37 | $0 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 12 | $0 |
2019
| Return visit (30+ min) | 110 | $577 |
| Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system | 27 | $4 |
2018
| Return visit (30+ min) | 207 | $2,504 |
| Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; dual lead pacemaker system | 38 | $0 |
Drugs they prescribed that Part D paid
$1,014,255
Pharmacies billed $1,014,255 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 1% of their Part D prescriptions (14 of 2,927) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
2,161 generic and 766 brand-name prescriptions · $1,014,255 in drug cost · 47 antibiotic prescriptions to 39 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 328 | $451,730 | $1,377 |
| Xarelto | 162 | $207,984 | $1,284 |
| Entresto | 72 | $88,543 | $1,230 |
| Multaq | 46 | $88,522 | $1,924 |
| Jardiance | 31 | $32,469 | $1,047 |
See all 47 drugs
| Eliquis | 328 | $451,730 | $1,377 |
| Xarelto | 162 | $207,984 | $1,284 |
| Entresto | 72 | $88,543 | $1,230 |
| Multaq | 46 | $88,522 | $1,924 |
| Jardiance | 31 | $32,469 | $1,047 |
| Farxiga | 19 | $26,810 | $1,411 |
| Repatha Sureclick | 14 | $20,902 | $1,493 |
| Brilinta | 14 | $13,178 | $941 |
| Praluent | 13 | $6,956 | $535 |
| Metoprolol | 299 | $5,126 | $17 |
| Propafenone Hcl Er | 11 | $4,784 | $435 |
| Potassium Chloride | 53 | $3,614 | $68 |
| Atorvastatin | 254 | $3,197 | $13 |
| Carvedilol | 216 | $2,070 | $10 |
| Amiodarone | 53 | $1,713 | $32 |
| Rosuvastatin | 80 | $1,570 | $20 |
| Flecainide Acetate | 33 | $1,543 | $47 |
| Bumetanide | 37 | $1,431 | $39 |
| Prasugrel | 18 | $1,359 | $75 |
| Digoxin | 28 | $1,129 | $40 |
| Isosorbide Mononitrate Er | 45 | $958 | $21 |
| Valsartan | 13 | $910 | $70 |
| Clopidogrel | 57 | $838 | $15 |
| Metoprolol | 98 | $771 | $8 |
| Ezetimibe | 27 | $682 | $25 |
| Lisinopril | 87 | $672 | $8 |
| Amlodipine Besylate | 103 | $631 | $6 |
| Diltiazem 24hr Er (Xr) | 18 | $630 | $35 |
| Hydralazine | 35 | $627 | $18 |
| Losartan | 86 | $606 | $7 |
| Diltiazem 24hr Er (Cd) | 16 | $573 | $36 |
| Nifedipine Er | 16 | $568 | $36 |
| Diltiazem | 12 | $416 | $35 |
| Nitroglycerin | 29 | $415 | $14 |
| Spironolactone | 57 | $414 | $7 |
| Furosemide | 95 | $406 | $4 |
| Diltiazem 24hr Er | 14 | $400 | $29 |
| Warfarin | 30 | $354 | $12 |
| Midodrine | 12 | $280 | $23 |
| Irbesartan | 11 | $277 | $25 |
| Colchicine | 14 | $220 | $16 |
| Sucralfate | 14 | $202 | $14 |
| Hydrochlorothiazide | 24 | $143 | $6 |
| Cephalexin | 20 | $112 | $6 |
| Triamterene-Hydrochlorothiazid | 14 | $110 | $8 |
| Hydrocodone-Acetaminophen | 13 | $48 | $4 |
| Amoxicillin | 12 | $13 | $1 |
Year by year
| 2024 | 2,927 | 1,109 | 1% (14) | 26% | $1,014,255 |
| 2023 | 4,046 | 1,336 | 0% (11) | 20% | $1,143,875 |
| 2022 | 3,151 | 1,041 | None | 19% | $804,693 |
| 2021 | 2,513 | 822 | None | 19% | $517,127 |
| 2020 | 2,225 | 672 | None | 23% | $397,355 |
| 2019 | 2,042 | 678 | None | 20% | $277,806 |
| 2018 | 2,217 | 675 | None | 16% | $208,986 |
| 2017 | 1,127 | 385 | None | None | $96,883 |
| 2016 | 743 | 161 | 3% (24) | 23% | $103,567 |
| 2015 | 196 | 84 | 11% (22) | 24% | $28,668 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 41 drugs
| Eliquis | 382 | $565,213 | $1,480 |
| Xarelto | 206 | $261,438 | $1,269 |
| Entresto | 53 | $70,630 | $1,333 |
| Multaq | 27 | $53,662 | $1,987 |
| Brilinta | 29 | $35,159 | $1,212 |
| Metoprolol | 525 | $13,920 | $27 |
| Praluent | 15 | $12,142 | $809 |
| Atorvastatin | 434 | $9,696 | $22 |
| Carvedilol | 310 | $7,078 | $23 |
| Amlodipine Besylate | 212 | $3,751 | $18 |
| Flecainide Acetate | 51 | $3,604 | $71 |
| Rosuvastatin | 113 | $3,544 | $31 |
| Prasugrel | 22 | $3,052 | $139 |
| Diltiazem 24hr Er (Cd) | 44 | $2,430 | $55 |
| Digoxin | 57 | $2,414 | $42 |
| Isosorbide Mononitrate Er | 54 | $2,143 | $40 |
| Amiodarone | 41 | $2,006 | $49 |
| Potassium Chloride | 50 | $1,875 | $38 |
| Warfarin | 80 | $1,748 | $22 |
| Losartan | 95 | $1,742 | $18 |
| Isosorbide Dinitrate | 20 | $1,723 | $86 |
| Ezetimibe | 28 | $1,710 | $61 |
| Lisinopril | 122 | $1,591 | $13 |
| Clopidogrel | 77 | $1,446 | $19 |
| Diltiazem 24hr Er (Xr) | 17 | $1,438 | $85 |
| Furosemide | 168 | $1,422 | $8 |
| Metoprolol | 128 | $1,378 | $11 |
| Nitroglycerin | 71 | $1,337 | $19 |
| Nifedipine Er | 18 | $1,224 | $68 |
| Bumetanide | 26 | $1,100 | $42 |
| Hydralazine | 52 | $1,083 | $21 |
| Diltiazem 24hr Er | 24 | $840 | $35 |
| Valsartan | 18 | $835 | $46 |
| Irbesartan | 22 | $695 | $32 |
| Spironolactone | 55 | $681 | $12 |
| Diltiazem | 13 | $454 | $35 |
| Hydrochlorothiazide | 41 | $272 | $7 |
| Colchicine | 16 | $241 | $15 |
| Triamterene-Hydrochlorothiazid | 12 | $218 | $18 |
| Sucralfate | 13 | $211 | $16 |
| Pantoprazole | 12 | $112 | $9 |
2022: 37 drugs
| Eliquis | 319 | $454,162 | $1,424 |
| Xarelto | 110 | $140,697 | $1,279 |
| Entresto | 35 | $40,523 | $1,158 |
| Pradaxa | 17 | $25,066 | $1,474 |
| Brilinta | 16 | $20,939 | $1,309 |
| Dofetilide | 13 | $13,958 | $1,074 |
| Metoprolol | 403 | $9,874 | $25 |
| Atorvastatin | 385 | $5,489 | $14 |
| Flecainide Acetate | 48 | $4,029 | $84 |
| Carvedilol | 246 | $3,891 | $16 |
| Potassium Chloride | 46 | $3,338 | $73 |
| Isosorbide Dinitrate | 20 | $2,966 | $148 |
| Rosuvastatin | 67 | $2,856 | $43 |
| Diltiazem 24hr Er (Cd) | 48 | $2,611 | $54 |
| Digoxin | 36 | $2,160 | $60 |
| Valsartan | 18 | $1,767 | $98 |
| Bumetanide | 15 | $1,608 | $107 |
| Warfarin | 59 | $1,496 | $25 |
| Amiodarone | 38 | $1,485 | $39 |
| Nitroglycerin | 83 | $1,347 | $16 |
| Clopidogrel | 58 | $1,255 | $22 |
| Isosorbide Mononitrate Er | 54 | $1,191 | $22 |
| Amlodipine Besylate | 166 | $1,173 | $7 |
| Losartan | 93 | $1,093 | $12 |
| Ezetimibe | 12 | $971 | $81 |
| Furosemide | 117 | $964 | $8 |
| Nifedipine Er | 19 | $926 | $49 |
| Hydralazine | 32 | $771 | $24 |
| Lisinopril | 95 | $749 | $8 |
| Metoprolol | 96 | $717 | $7 |
| Spironolactone | 42 | $609 | $15 |
| Olmesartan Medoxomil | 13 | $592 | $46 |
| Hydrochlorothiazide | 48 | $359 | $7 |
| Verapamil Er | 13 | $333 | $26 |
| Klor-Con 10 | 11 | $243 | $22 |
| Atenolol | 18 | $199 | $11 |
| Triamterene-Hydrochlorothiazid | 12 | $50 | $4 |
2021: 34 drugs
| Eliquis | 231 | $271,138 | $1,174 |
| Xarelto | 77 | $104,283 | $1,354 |
| Entresto | 30 | $31,190 | $1,040 |
| Pradaxa | 23 | $30,960 | $1,346 |
| Metoprolol | 297 | $7,868 | $26 |
| Flecainide Acetate | 44 | $4,334 | $98 |
| Atorvastatin | 281 | $3,950 | $14 |
| Carvedilol | 208 | $2,694 | $13 |
| Diltiazem 24hr Er (Cd) | 32 | $2,485 | $78 |
| Isosorbide Dinitrate | 14 | $2,469 | $176 |
| Bumetanide | 23 | $2,321 | $101 |
| Rosuvastatin | 49 | $2,294 | $47 |
| Potassium Chloride | 54 | $1,948 | $36 |
| Digoxin | 33 | $1,709 | $52 |
| Nifedipine Er | 26 | $1,488 | $57 |
| Isosorbide Mononitrate Er | 54 | $1,248 | $23 |
| Warfarin | 49 | $1,224 | $25 |
| Nitroglycerin | 73 | $1,210 | $17 |
| Losartan | 82 | $1,196 | $15 |
| Valsartan | 23 | $1,184 | $51 |
| Ezetimibe | 17 | $1,127 | $66 |
| Amlodipine Besylate | 155 | $1,109 | $7 |
| Clopidogrel | 55 | $1,010 | $18 |
| Dilt-Xr | 11 | $887 | $81 |
| Furosemide | 109 | $816 | $7 |
| Hydralazine | 35 | $777 | $22 |
| Metoprolol | 69 | $666 | $10 |
| Spironolactone | 41 | $622 | $15 |
| Lisinopril | 64 | $540 | $8 |
| Diltiazem 24hr Er | 11 | $492 | $45 |
| Verapamil Er | 12 | $379 | $32 |
| Amiodarone | 18 | $335 | $19 |
| Hydrochlorothiazide | 36 | $235 | $7 |
| Atenolol | 11 | $116 | $11 |
2020: 33 drugs
| Eliquis | 210 | $175,538 | $836 |
| Xarelto | 91 | $101,983 | $1,121 |
| Pradaxa | 20 | $21,739 | $1,087 |
| Entresto | 25 | $21,230 | $849 |
| Multaq | 15 | $14,970 | $998 |
| Metoprolol | 251 | $8,052 | $32 |
| Brilinta | 11 | $6,119 | $556 |
| Atorvastatin | 248 | $3,357 | $14 |
| Flecainide Acetate | 22 | $3,002 | $136 |
| Digoxin | 37 | $2,025 | $55 |
| Carvedilol | 217 | $1,891 | $9 |
| Isosorbide Dinitrate | 14 | $1,747 | $125 |
| Potassium Chloride | 49 | $1,719 | $35 |
| Rosuvastatin | 31 | $1,641 | $53 |
| Hydralazine | 53 | $1,429 | $27 |
| Bumetanide | 29 | $1,338 | $46 |
| Nifedipine Er | 16 | $1,309 | $82 |
| Nitroglycerin | 85 | $1,276 | $15 |
| Valsartan | 13 | $1,070 | $82 |
| Diltiazem 24hr Er (Cd) | 25 | $911 | $36 |
| Isosorbide Mononitrate Er | 40 | $782 | $20 |
| Amlodipine Besylate | 132 | $734 | $6 |
| Losartan | 62 | $709 | $11 |
| Metoprolol | 101 | $551 | $5 |
| Clopidogrel | 34 | $531 | $16 |
| Furosemide | 81 | $506 | $6 |
| Amiodarone | 11 | $413 | $38 |
| Warfarin | 18 | $384 | $21 |
| Spironolactone | 24 | $365 | $15 |
| Lisinopril | 57 | $352 | $6 |
| Verapamil Er | 12 | $342 | $29 |
| Hydrochlorothiazide | 27 | $214 | $8 |
| Atenolol | 12 | $72 | $6 |
2019: 32 drugs
| Eliquis | 161 | $103,122 | $641 |
| Xarelto | 93 | $80,721 | $868 |
| Pradaxa | 11 | $13,687 | $1,244 |
| Entresto | 15 | $12,927 | $862 |
| Metoprolol | 285 | $9,969 | $35 |
| Brilinta | 15 | $7,516 | $501 |
| Atorvastatin | 228 | $4,385 | $19 |
| Flecainide Acetate | 12 | $2,291 | $191 |
| Carvedilol | 171 | $2,070 | $12 |
| Potassium Chloride | 44 | $1,781 | $40 |
| Rosuvastatin | 18 | $1,767 | $98 |
| Digoxin | 22 | $1,174 | $53 |
| Nitroglycerin | 69 | $1,046 | $15 |
| Isosorbide Dinitrate | 14 | $1,025 | $73 |
| Isosorbide Mononitrate Er | 36 | $1,001 | $28 |
| Diltiazem 24hr Er (Cd) | 21 | $988 | $47 |
| Bumetanide | 17 | $844 | $50 |
| Ezetimibe | 13 | $774 | $60 |
| Losartan | 64 | $740 | $12 |
| Warfarin | 37 | $701 | $19 |
| Amlodipine Besylate | 107 | $664 | $6 |
| Hydralazine | 39 | $661 | $17 |
| Cartia Xt | 14 | $610 | $44 |
| Clopidogrel | 38 | $442 | $12 |
| Spironolactone | 31 | $439 | $14 |
| Furosemide | 77 | $403 | $5 |
| Metoprolol | 59 | $367 | $6 |
| Lisinopril | 42 | $355 | $8 |
| Pravastatin | 11 | $354 | $32 |
| Hydrochlorothiazide | 27 | $165 | $6 |
| Atenolol | 23 | $147 | $6 |
| Amoxicillin | 11 | $16 | $1 |
2018: 33 drugs
| Eliquis | 118 | $81,604 | $692 |
| Xarelto | 69 | $44,942 | $651 |
| Pradaxa | 33 | $17,079 | $518 |
| Metoprolol | 277 | $8,821 | $32 |
| Brilinta | 15 | $8,425 | $562 |
| Atorvastatin | 247 | $2,777 | $11 |
| Ezetimibe | 14 | $2,115 | $151 |
| Potassium Chloride | 25 | $1,863 | $75 |
| Nitroglycerin | 74 | $1,677 | $23 |
| Diltiazem 24hr Er (Cd) | 52 | $1,631 | $31 |
| Isosorbide Mononitrate Er | 93 | $1,533 | $16 |
| Carvedilol | 181 | $1,279 | $7 |
| Dilt-Xr | 24 | $1,079 | $45 |
| Cartia Xt | 34 | $1,076 | $32 |
| Amiodarone | 18 | $1,047 | $58 |
| Verapamil Er | 15 | $834 | $56 |
| Warfarin | 62 | $814 | $13 |
| Digoxin | 14 | $671 | $48 |
| Isosorbide Dinitrate | 11 | $669 | $61 |
| Hydralazine | 46 | $616 | $13 |
| Clopidogrel | 41 | $605 | $15 |
| Diltiazem 24hr Er | 17 | $605 | $36 |
| Amlodipine Besylate | 118 | $583 | $5 |
| Rosuvastatin | 15 | $583 | $39 |
| Losartan | 86 | $533 | $6 |
| Diltiazem | 17 | $432 | $25 |
| Metoprolol | 90 | $371 | $4 |
| Furosemide | 72 | $318 | $4 |
| Lisinopril | 52 | $280 | $5 |
| Atenolol | 22 | $179 | $8 |
| Spironolactone | 18 | $138 | $8 |
| Losartan-Hydrochlorothiazide | 17 | $131 | $8 |
| Hydrochlorothiazide | 17 | $96 | $6 |
2017: 30 drugs
| Eliquis | 38 | $19,503 | $513 |
| Xarelto | 20 | $9,115 | $456 |
| Metformin Hcl Er | 11 | $5,560 | $505 |
| Zetia | 15 | $5,258 | $351 |
| Pradaxa | 12 | $4,627 | $386 |
| Metoprolol | 85 | $2,261 | $27 |
| Atorvastatin | 83 | $1,087 | $13 |
| Nitroglycerin | 24 | $666 | $28 |
| Carvedilol | 108 | $535 | $5 |
| Cartia Xt | 16 | $432 | $27 |
| Potassium Chloride | 13 | $401 | $31 |
| Nitrostat | 12 | $392 | $33 |
| Losartan | 20 | $338 | $17 |
| Isosorbide Mononitrate Er | 20 | $246 | $12 |
| Lisinopril | 34 | $213 | $6 |
| Amlodipine Besylate | 44 | $201 | $5 |
| Warfarin | 16 | $185 | $12 |
| Hydralazine | 16 | $169 | $11 |
| Clopidogrel | 21 | $159 | $8 |
| Hydrochlorothiazide | 24 | $145 | $6 |
| Glipizide | 11 | $110 | $10 |
| Furosemide | 22 | $109 | $5 |
| Sertraline | 12 | $106 | $9 |
| Pantoprazole | 12 | $105 | $9 |
| Spironolactone | 13 | $100 | $8 |
| Atenolol | 16 | $97 | $6 |
| Alendronate | 11 | $90 | $8 |
| Metoprolol | 26 | $90 | $3 |
| Losartan-Hydrochlorothiazide | 13 | $63 | $5 |
| Cephalexin | 11 | $46 | $4 |
2016: 17 drugs
| Metformin Hcl Er | 15 | $47,942 | $3,196 |
| Zetia | 18 | $6,591 | $366 |
| Lantus Solostar | 13 | $4,438 | $341 |
| Levothyroxine | 32 | $667 | $21 |
| Atorvastatin | 26 | $434 | $17 |
| Methylprednisolone | 24 | $404 | $17 |
| Gabapentin | 25 | $396 | $16 |
| Hydrocodone-Acetaminophen | 14 | $224 | $16 |
| Losartan | 19 | $203 | $11 |
| Zolpidem | 11 | $199 | $18 |
| Azithromycin | 20 | $160 | $8 |
| Simvastatin | 16 | $145 | $9 |
| Carvedilol | 18 | $140 | $8 |
| Pantoprazole | 19 | $140 | $7 |
| Amlodipine Besylate | 22 | $134 | $6 |
| Sertraline | 14 | $127 | $9 |
| Metformin | 12 | $74 | $6 |
2015: 2 drugs
| Methylprednisolone | 11 | $222 | $20 |
| Hydrocodone-Acetaminophen | 12 | $174 | $14 |
Money from drug and device companies
$269 in 2025
| 2025 | 3 | 5 | None | $269 |
| 2024 | 4 | 5 | None | $517 |
| 2022 | 1 | 1 | None | $20 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Heartflow | Ffrct | $167 | 1 payment
|
| Abbott Laboratories | Aveir | $64 | 3 payments
|
| Boston Scientific | Lux-Dx Insertable Cardiac Monitor | $38 | 1 payment
|
See all 5 published payments
| Boston Scientific | Meals · 2025-07-31 | Lux-Dx Insertable Cardiac Monitor | $38 |
| Heartflow | Meals · 2025-05-15 | Ffrct | $167 |
| Abbott Laboratories | Meals · 2025-01-07 | Aveir | $18 |
| Abbott Laboratories | Meals · 2025-01-07 | Aveir | $22 |
| Abbott Laboratories | Meals · 2025-01-07 | Aveir | $25 |
See earlier years (2024, 2022)
2024: $517
| iRhythm Technologies | Zio Xt Patch | $211 | 2 payments
|
| Medtronic | Selectsecure | $164 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $121 | 1 payment
|
| Abbott Laboratories | Aveir | $21 | 1 payment
|
2022: $20
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $20 | 1 payment
|
Professional record
- NPI
- 1891173027
- Licence
- CA 52223
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 1450 Treat Blvd Ste 300, Walnut Creek, CA, 94597
- NPI first listed
- 2015-05-07
- NPI last updated
- 2026-07-02
- NPI record certified
- 2026-07-02
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 20130 Lake Chabot Rd, Castro Valley, CA, 94546 · 350 Hawthorne Ave, Oakland, CA, 94609